May 31, 2021 10:53 AM IST
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well
- May 24, 2021 07:19 PM IST
Favipiravir is being used for patients with mild to moderate COVID-19 infection as it inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.
- May 10, 2021 12:57 PM IST
Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.
- Apr 12, 2021 09:50 PM IST
With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?
- Nov 23, 2020 02:17 PM IST
Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus’s replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient, Glenmark said.
- Oct 29, 2020 03:52 PM IST
Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug
- Oct 29, 2020 02:56 PM IST
Advocate M L Sharma petitioner in-person referred to the bench, also comprising Justices A S Bopanna and V Ramasubramanian, the World Health Organization (WHO) report of October 15 and said that nowhere these medicines are designated officially as medicines for coronavirus.
- Aug 25, 2020 07:45 PM IST
The Drug Controller General of India (DCGI) had earlier approved the use of Favipiravir, an off patent, oral antiviral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms, FDC said in a statement.
- Aug 10, 2020 08:15 AM IST
Cipla's US revenues clocked a sequential improvement to about $135 million, backed by a ramp-up in the generic version of gProventil HFA
- Aug 05, 2020 05:10 PM IST
The tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenar's US FDA approved facility here, a press release from the drug maker said.
- Aug 05, 2020 03:00 PM IST
The company has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to purchase the medicine at a highly subsidised rate, BDR Pharmaceuticals said in a statement.
- Aug 05, 2020 12:55 PM IST
Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.
- Jul 29, 2020 12:10 PM IST
The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.
- Jul 27, 2020 08:15 PM IST
The company, in a press release, said it has developed an alternative low cost and highly efficient manufacturing process and is now supplying commercial quantities to drug maker Cipla for the launch of Ciplenza, the generic version of Favipiravir.
- Jul 24, 2020 08:25 PM IST
Favipiravir, which is known to quicken the pace of clinical recovery of COVID-19 patients, is an oral anti-viral drug under the brand name Ciplenza
- Jul 23, 2020 07:41 PM IST
To be available in 200 mg tablets, the drug will be sold at a maximum retail price of Rs 59 per tablet, Brinton Pharmaceuticals said in a statement.
- Jul 21, 2020 10:30 AM IST
On July 13, Glenmark Pharmaceuticals cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, by 27 percent to Rs 75 per tablet.
- Jul 19, 2020 08:30 PM IST
Glenmark Pharmaceuticals had on July 13 said it has cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet.
- Jul 19, 2020 01:33 PM IST
DCGI issued notices based on a representation by a Member of Parliament (MP), who complained about the cost of the drug and the false claims.
- Jul 14, 2020 01:45 PM IST
Besides DCGI's nod to produce the active pharmaceutical ingredient in India, it has been cleared for exports as well.
- Jun 26, 2020 07:40 AM IST
"We have decided to buy Remdesivir and Favipiravir as well as other essential drugs to treat COVID-19 patients in large numbers. The drugs are costly so the state has decided to buy them itself," he told reporters here.
- Jun 22, 2020 08:27 PM IST
Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, said drugs such as Favipiravir and Remdisiver "cannot be called game changers" as they are used as a supportive treatment.
- Jun 19, 2020 03:36 PM IST
Sources told Moneycontrol that Glenmark's Favipiravir is expected to get approval from drug regulator any moment, based on the intermediate data from the clinical trials given the urgency of the situation
- May 13, 2020 07:26 PM IST
The science and technology ministry has reportedly earmarked 42 existing drugs, narrowed down from a list of at least 2,100 approved drugs, for repurposing.
- May 05, 2020 09:29 AM IST